Correlation analysis and prognostic value of miR-29a-3p expression and CYP2C19 genotypes in exfoliated cells from tongue coating of patients with gastroesophageal reflux disease

[1]  Li-Juan Zhao,et al.  Identification of the upstream regulators of KDM5B in gastric cancer. , 2022, Life sciences.

[2]  S. Olmi,et al.  Effect of laparoscopic sleeve gastrectomy vs laparoscopic sleeve + Rossetti fundoplication on weight loss and de novo GERD in patients affected by morbid obesity: a randomized clinical study , 2022, Obesity Surgery.

[3]  W. M. Abd El Maksoud,et al.  Impact of Laparoscopic Sleeve Gastrectomy on Gastroesophageal Reflux Disease and Risk Factors Associated with Its Occurrence Based Upon Quality of Life , 2021, Obesity Surgery.

[4]  R. Buchaim,et al.  Updates in association of gastroesophageal reflux disease and dental erosion: systematic review , 2021, Expert review of gastroenterology & hepatology.

[5]  A. A. Trespalacios-Rangel,et al.  Prevalence of CYP2C19 polymorphism in Bogotá, Colombia: The first report of allele *17 , 2021, PloS one.

[6]  Yi-Hau Chen,et al.  The association between depression and gastroesophageal reflux based on phylogenetic analysis of miRNA biomarkers. , 2020, Current medicinal chemistry.

[7]  K. Satyamoorthy,et al.  Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases. , 2020, Life sciences.

[8]  M. Kadakia,et al.  Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus , 2020, Clinical and translational gastroenterology.

[9]  S. Kolli,et al.  The Effect of Laparoscopic Sleeve Gastrectomy on Gastroesophageal Reflux Disease , 2018, Obesity Surgery.

[10]  U. Zanger,et al.  MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation. , 2019, Biochemical pharmacology.

[11]  Kristle L. Lynch,et al.  The role of diet in the development and management of gastroesophageal reflux disease: why we feel the burn. , 2019, Journal of thoracic disease.

[12]  Julie A. Johnson,et al.  Novel Implementation of Genotype‐Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial , 2018, Clinical and translational science.

[13]  Tyrone D. Cannon,et al.  The NDE1 genomic locus can affect treatment of psychiatric illness through gene expression changes related to microRNA-484 , 2016, European Neuropsychopharmacology.

[14]  E. Savarino,et al.  Modern diagnosis of GERD: the Lyon Consensus , 2018, Gut.

[15]  R. Kellerman,et al.  Gastroesophageal Reflux Disease. , 2017, Primary care.

[16]  M. Fassan,et al.  Noncoding RNAs as drivers of the phenotypic plasticity of oesophageal mucosa , 2017, World journal of gastroenterology.

[17]  Toshio Watanabe,et al.  Expression of Serum Exosomal and Esophageal MicroRNA in Rat Reflux Esophagitis , 2017, International journal of molecular sciences.

[18]  M. Hirai,et al.  Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy , 2017, World journal of gastroenterology.

[19]  Hui Zhang,et al.  miR-203 Expression in Exfoliated Cells of Tongue Coating Represents a Sensitive and Specific Biomarker of Gastroesophageal Reflux Disease , 2016, Gastroenterology research and practice.

[20]  A. Andoh,et al.  Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis , 2016, Journal of gastroenterology and hepatology.

[21]  H. El‐Serag,et al.  Lifestyle Intervention in Gastroesophageal Reflux Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  A. Bansal,et al.  A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett’s Esophagus , 2016, Digestive Diseases and Sciences.

[23]  N. Mei,et al.  MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells. , 2015, Biochemical pharmacology.

[24]  D. Sifrim,et al.  Pepsin in saliva for the diagnosis of gastro-oesophageal reflux disease , 2014, Gut.

[25]  Jin-Jo Kim,et al.  Upper Gastrointestinal Cancer and Reflux Disease , 2013, Journal of gastric cancer.

[26]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[27]  M. Michael,et al.  Impact of gastro-oesophageal reflux on microRNA expression, location and function , 2013, BMC Gastroenterology.

[28]  Shao Li,et al.  Integrating next-generation sequencing and traditional tongue diagnosis to determine tongue coating microbiome , 2012, Scientific Reports.

[29]  T. Furuta,et al.  Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19. , 2012, Molecular diagnosis & therapy.

[30]  B. Ning,et al.  Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[31]  Yasuhiro Aoki,et al.  Human CYP2E1 is regulated by miR-378. , 2010, Biochemical pharmacology.

[32]  R. Ward,et al.  Single-dose, multiple-dose, and population pharmacokinetics of pantoprazole in neonates and preterm infants with a clinical diagnosis of gastroesophageal reflux disease (GERD) , 2010, European Journal of Clinical Pharmacology.

[33]  Yuzhuo Pan,et al.  MicroRNAs Regulate CYP3A4 Expression via Direct and Indirect Targeting The online version of this article (available at http://dmd.aspetjournals.org) contains supplemental material. , 2009, Drug Metabolism and Disposition.

[34]  H. El‐Serag.  The Association Between Obesity and GERD: A Review of the Epidemiological Evidence , 2008, Digestive Diseases and Sciences.

[35]  Shingo Takagi,et al.  MicroRNA regulates the expression of human cytochrome P450 1B1. , 2006, Cancer research.

[36]  T. Koike,et al.  The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism , 2003, Alimentary pharmacology & therapeutics.

[37]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[38]  R. Edwards,et al.  Diazinon is activated by CYP2C19 in human liver. , 2001, Toxicology and applied pharmacology.

[39]  J. Pandolfino,et al.  Smoking and gastro-oesophageal reflux disease. , 2000, European journal of gastroenterology & hepatology.

[40]  J. Salo,et al.  Gastroesophageal reflux disease as a cause of death: analysis of fatal cases under conservative treatment. , 1999, Scandinavian journal of gastroenterology.

[41]  P. Brady,et al.  Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment , 1998, Drugs of today.